GlassScriptPhysician profile
Laura E Ferguson-Weigman
NPI 1306244769
$5,119.04
in general payments reported to CMS, 2019-2025
35 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $397 · 2023: $1,903 · 2024: $1,449 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,721.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.35 | 2023-2025 | |
| Novo Nordisk INC | $636.62 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $625.02 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $363.30 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $266.19 | 2022-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $237.09 | 2023-2025 | |
| Amgen INC. | $215.09 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $186.90 | 2022-2025 | Rexulti |
| Pfizer INC. | $170.54 | 2024-2025 | |
| Lundbeck LLC | $144.90 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $139.46 | 2022-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.20 | 2022-2024 | Jardiance, Synjardy |
| Grifols USA, LLC | $119.49 | 2022-2024 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $108.26 | 2022-2025 | Camzyos, Eliquis |
| Optinose US, INC. | $93.00 | 2023-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $88.84 | 2023-2024 | Wakix |
| Merck Sharp & Dohme LLC | $86.78 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Vifor Pharma, INC. | $86.25 | 2024-2025 | Zemaira |
| Exact Sciences Corporation | $85.93 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $84.08 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.62 | 2023-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $62.62 | 2023-2025 | Korlym |
| Neurocrine Biosciences, INC. | $61.33 | 2023 | Ingrezza |
| Esperion Therapeutics, INC. | $60.40 | 2024-2025 | Nexletol |
| Horizon Therapeutics Plc | $53.66 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $50.70 | 2023-2025 | Sunosi, Auvelity |
| Myriad Women'S Health, INC. | $42.11 | 2023 | Myrisk |
| Dexcom, INC. | $40.72 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $36.98 | 2023-2025 | Gemtesa |
| Baxter Healthcare | $34.81 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $34.48 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.57 | 2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $14.71 | 2023 | Airduo Digihaler |
| Verona Pharma, INC. | $14.33 | 2025 | Ohtuvayre |
| Globus Medical, INC. | $13.71 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ferguson-Weigman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.